Product Details
Source
Monoclonal Anti-Human 4-1BB Antibody, Mouse IgG1 is a chimeric monoclonal antibody recombinantly produced from CHO cells, which combines the variable region of a human monoclonal antibody with mouse IgG1 constant domain, which provides higher batch consistency and long term security of supply.
Antibody Type
Recombinant Monoclonal
Isotype
Mouse IgG1, Kappa
Host Species
Rabbit
Conjugate
PE
Excitation Wavelength: 488 nm / 561 nm
Emission Wavelength: 575 nm
Application
Flow Cytometry (Detection the expression of 4-1BB on Human cells).
Recommended Dilution
1:20
Isotype Control
The isotype control is sold separately; please refer to Cat. No. DNP-PM1 for product information.
Form
Liquid
Formulation
Supplied as 0.2 μm-filtered solution in PBS (pH 7.4) containing 0.03% ProClin 300 and 0.2% BSA, with trehalose as protectant.
Please contact us for customized product forms or formulations.
Shipping
Liquid product is shipped at blue ice.
Storage
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- Store at 2-8 °C for 12 months.
Notices
Product Specific Notices: For research use only.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Bioactivity-FACS

Flow cytometric analysis of HEK293/Human 4-1BB / TNFRSF9 Stable Cell Line staining with PE-Labeled Monoclonal Anti-Human 4-1BB Antibody, Mouse IgG1 (Cat. No. FABm038-01) at 1:20 dilution (5 μL of the antibody stock solution corresponds to labeling of 1e6 cells in a final volume of 100 µL), compared with isotype control antibody. PE signal was used to evaluate the binding activity (QC tested).
Protocol
Customer Reviews Writing Reviews

Background
4-1BB activation enhances CD8 T cell and NK cell mediated anti-tumor immunity . It also contributes to the development of inflammation in high fat diet-induced metabolic syndrome . Soluble forms of 4-1BB and 4-1BB Ligand circulate at elevated levels in the serum of rheumatoid arthritis and hematologic cancer patients, respectively .
Recent Advances
- English Name:
Tumor necrosis factor receptor superfamily member 9
- Category:
- Approved Drugs:
0 Details
- Drugs in Clinical Trials:
77 Details
- Highest Development Stage:
Phase 3 Clinical



















